Research areas and methodologies
RESEARCH INTERESTS
- Preclinical and clinical evaluation of cardiovascular toxicity induced by approved or investigational anticancer drugs (anthracyclines, anthracenediones, taxanes, tyrosine kinase inhibitors with activity on FLT3++ acute myeloid leukemia, Ph++ T315I+/--acute lymphoblastic leukemia,+ T315I+/-chronic myeloid leukemia, indoleamine 2,3-dioxygenase inhibitors)
- Pharmacokinetics of tyrosine kinase inhibitors in hematological patients
- Pharmacokinetics of antifungal drugs in hematological patients
- Development and validation of analytical methods for Therapeutic Drug Monitoring
INVESTIGATIONAL SETTINGS
- In vitro translational model of human heart exposed to clinically relevant concentrations of drugs and/or drug combinations for monitoring cardiac pharmacokinetics and metabolism
- cell lines
- cell lines and cell-free systems for structure-activity and metabolism studies
- Hematological and oncological patients at risk of cardiovascular events during chemotherapy regimens
- Hematological patients at risk of pharmacokinetic interactions between antifungals and tyrosine kinase inhibitors
MAIN RESEARCH METHODOLOGIES
- Cell culture and tissue samples
- UV/VIS/NIR spectroscopy
- High Performance Lquid Chromatography
- Tandem Mass Spectrometry
- Good Laboratory Practices and Good Clinical Practices
Collaborations with other Research Centers
- Abramson Cancer Center, Philadelphia, PA
- University of Pennsylvania School of Medicine, Philadelphia, PA
- MD Anderson Cancer Institute, Houston, TX
- IRCCS Fondazione Policlinico Gemelli, Rome
- University of Tor Vergata, Rome
Patents
Methods for reducing toxicity of combined chemotherapies
- LD0226 (co-sharing with Bristol Myers Squibb, USA)
- LD0231 (co-sharing with Bristol Myers Squibb, USA)
LABORATORIES
- PRABB, Preclinical Pharmacology laboratory
- Campus Bio-Medico University Hospital Foundation, Clinical Pharmacology laboratory